Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Personalis, Inc.
  6. Summary
    PSNL   US71535D1063

PERSONALIS, INC.

(PSNL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
18.96(c) 19.84(c) 19.6(c) 19.45(c) 18.95(c) Last
252 612 251 241 182 798 184 365 113 567 Volume
-4.91% +4.64% -1.21% -0.77% -2.57% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 85,1 M - -
Net income 2021 -67,9 M - -
Net cash position 2021 287 M - -
P/E ratio 2021 -12,2x
Yield 2021 -
Sales 2022 83,1 M - -
Net income 2022 -91,4 M - -
Net cash position 2022 219 M - -
P/E ratio 2022 -8,83x
Yield 2022 -
Capitalization 842 M 842 M -
EV / Sales 2021 6,52x
EV / Sales 2022 7,49x
Nbr of Employees 235
Free-Float 97,8%
More Financials
Company
Personalis, Inc. is a cancer genomics company. The Company is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The Company provides sequencing and data analysis services to support the development of cancer therapies. The Company has designed NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes,... 
More about the company
Ratings of Personalis, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about PERSONALIS, INC.
10/21PERSONALIS : to Announce Third Quarter Financial Results on November 4, 2021
BU
10/15INSIDER SELL : Personalis
MT
10/13PERSONALIS : Expands Leadership Team With Appointment of Robert Bruce, Vice President of R..
BU
10/12PERSONALIS : Mayo Clinic Collaborate to Provide Cancer Genomic Testing
MT
10/12PERSONALIS : Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testin..
BU
10/12Mayo Clinic Collaborates With Personalis Inc. to Expand Cancer Genomic Testing
CI
10/07PERSONALIS : Prevailing Cancer Immunotherapy Challenges
PU
09/30PERSONALIS : Prevailing Cancer Immunotherapy Challenges
PU
09/21PERSONALIS : BTIG Adjusts Personalis' Price Target to $30 from $35, Keeps Buy Rating
MT
09/20PERSONALIS : Needham & Co Adjusts Personalis PT to $28 From $33, Maintains Buy Rating
MT
09/20PERSONALIS : Gets New Task Order Totaling Up to $10 Million; Reiterates Q3, Full-Year Outl..
MT
09/18PERSONALIS : Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Cust..
BU
09/18Personalis, Inc. Re-Affirms Earnings Guidance for the Third Quarter and Full Year of Fi..
CI
08/26PERSONALIS : to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
BU
08/25PERSONALIS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financ..
AQ
More news
News in other languages on PERSONALIS, INC.
10/12Personalis et la Mayo Clinic collaborent pour fournir des tests génomiques du cancer
09/20Personalis obtient un nouveau contrat d'un montant total de 10 millions de dollars et r..
09/18Personalis, Inc. réaffirme ses prévisions de résultats pour le troisième trimestre et l..
08/03PERSONALIS, INC. : publica nuevos datos sobre el nuevo biomarcador compuesto NEOPS™ ..
08/03PERSONALIS, INC. : publiceert nieuwe gegevens die een nieuwe samengestelde biomarker NEOPS..
More news
Analyst Recommendations on PERSONALIS, INC.
More recommendations
Chart PERSONALIS, INC.
Duration : Period :
Personalis, Inc. Technical Analysis Chart | PSNL | US71535D1063 | MarketScreener
Technical analysis trends PERSONALIS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 18,95 $
Average target price 32,14 $
Spread / Average Target 69,6%
EPS Revisions
Managers and Directors
John S. West President, Chief Executive Officer & Director
Aaron Tachibana Chief Financial Officer
Jonathan J. MacQuitty Chairman
Richard O. Chen Chief Scientific Officer
Xavier Paliard Vice President-Immunology, Research & Development
Sector and Competitors
1st jan.Capi. (M$)
PERSONALIS, INC.-48.24%842
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455